Lymphoma drug combo trial halted early – what we learned
NCT ID NCT03769181
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tested a combination of two drugs, isatuximab and cemiplimab, in people with certain types of lymphoma that had come back or not responded to other treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, but researchers collected information on side effects and how well the drugs worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1580002
Taichung, 40447, Taiwan
-
Investigational Site Number :2500001
Villejuif, 94800, France
-
Investigational Site Number :2500002
Nantes, 44093, France
-
Investigational Site Number :2500004
Montpellier, 34295, France
-
Investigational Site Number :2500005
Dijon, 21000, France
-
Investigational Site Number :2500007
Pessac, 33600, France
-
Investigational Site Number :3800002
Bologna, 40138, Italy
-
Investigational Site Number :3800003
Rozzano, Milano, 20089, Italy
-
Investigational Site Number :3800006
Brescia, 25123, Italy
-
Investigational Site Number :4100001
Gangnam-gu, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number :4100002
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number :5280001
Maastricht, 6229 HX, Netherlands
-
Investigational Site Number :5280002
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number :6200002
Coimbra, 3000-075, Portugal
-
Investigational Site Number :6200003
Porto, 4200, Portugal
-
Investigational Site Number :6200004
Lisbon, 1649-035, Portugal
-
Investigational Site Number :7240002
L'Hospitalet de Llobregat, Barcelona [Barcelona], 08908, Spain
-
Investigational Site Number :7240003
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number :7240004
Madrid / Madrid, Madrid, Comunidad de, 28040, Spain
-
Investigational Site Number :7240005
Barcelona, Barcelona [Barcelona], 08036, Spain
Conditions
Explore the condition pages connected to this study.